Saudi Arabia – [22-04-2026] – Jamjoom Pharma, a leading Saudi pharmaceutical healthcare company in the Middle East and Africa (MEA), and Viatris Arabia Limited “LLC”, a part of global healthcare company Viatris, announced a local manufacturing agreement by which Jamjoom Pharma will manufacture several Viatris products for chronic diseases in the Kingdom of Saudi Arabia. The partnership reflects the two companies shared commitment to supporting Saudi Arabia’s Vision 2030 by advancing local manufacturing capabilities and contributing to sustainable access to high-quality medicines for patients across Saudi Arabia.Through this collaboration, Jamjoom Pharma will manufacture several products across multiple therapeutic areas from Viatris’ broad portfolio that is available to patients in KSA.

Tarek Hosni, CEO of Jamjoom Pharma, stated: “Through this strategic collaboration with Viatris, we are reinforcing Jamjoom Pharma’s position as a national manufacturer and healthcare partner and delivering on our long-standing commitment to enhancing local capabilities and contributing to improved access to high-quality medicines in Saudi Arabia.

Ayman Mokhtar, Regional President Middle East, North Africa and Eurasia for Viatris, added: “Viatris’ agreement with Jamjoom Pharma  will further strengthen our presence in the Kingdom and our  commitment to our mission to empower people worldwide to live healthier at every stage of life. We are keen to support KSA’s vision 2030 while working steadfastly to bring our innovative pipeline to patients for improved health outcomes.”